Nasus Pharma Announces Clinical Data Demonstrating Efficacy

NP-003 study terminated early with high significance in reducing viral infection. TEL AVIV , Israel, Nov. 24, 2021 /PRNewswire/ -- Nasus Pharma a privately held clinical-stage biopharmaceutical

Related Keywords

Bulgaria , United States , Canada , Israel , America , Barbaraj Mann , Ella Mendelson , H Hypromellose Taffix , Nasus Pharma , Micha Gladnikoff , Prnewswire Nasus Pharma , Megiddo Dalia , G Brett Moreau , Kostenloser Wertpapierhandel , Yaron Drori , Klang Shmuel , Dalia Megiddo , Michal Mandelboim , Naparstek Yaakov , Udi Gilboa , Nasus Pharma Ltd , Biomedical Research , Common Cold , Upper Respiratory Infection , Upper Respiratory Infections , Dalia Megiddo Chief Executive Officer , Executive Chairman , Upper Respiratory , South America , Middle East , Intranasal Naloxone , Intranasal Epinephrine , Lapidot Tair , Expert Review , Anti Infective Therapy , Tair Lapidot , Taffix Nasal Powder , Effective Barrier , Tech Res , Nofar Atari , Taffix Nasal Powder Spray Forms , Effective Barrier Against Infectious New Variants , Nasus , Dharma , Nnounces , Linical , Data , Emonstrating , Efficacy , Taffix , Intranasal , Antiviral , Protection , Against , Common , Gold , Supper , Espiratory , Infection ,